Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
XDEMVY vs ABSTRAL
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
XDEMVY (lotilaner ophthalmic solution) is a gamma-aminobutyric acid (GABA)-gated chloride channel antagonist. It inhibits the GABA-gated chloride channels in Demodex mites, leading to paralysis and death of the mites.
Fentanyl is a potent mu-opioid receptor agonist, producing analgesia and sedation by activating G-protein coupled opioid receptors in the central nervous system.
Treatment of Demodex blepharitis
Management of breakthrough pain in cancer patients aged 18 and older who are already receiving and tolerant to around-the-clock opioid therapy for their underlying persistent cancer pain.
1 drop in each eye once daily in the evening for 6 weeks.
For breakthrough pain in opioid-tolerant patients: initial dose 100 mcg sublingual tablet, titrate across strengths (100, 200, 300, 400, 600, 800 mcg) as needed; maximum 2 doses per episode, minimum 2 hours between episodes.
Terminal elimination half-life of approximately 4-6 hours; clinically, steady-state is reached within 24-36 hours.
Terminal elimination half-life: 6-10 hours (mean 8 hours); prolonged in elderly and hepatic impairment
Lotilaner is metabolized via cytochrome P450 (CYP) enzymes, primarily CYP3A4, and to a lesser extent CYP2C9 and CYP2C19.
Hepatic metabolism primarily via CYP3A4; major metabolites include norfentanyl (inactive) and other minor metabolites.
Primary renal excretion as unchanged drug and metabolites; ~70% in urine. Biliary/fecal excretion accounts for ~25%.
Renal: ~70% as metabolites (primarily fentanyl conjugates and norfentanyl), ~10% unchanged; Fecal: ~9%; Biliary: minimal
Approximately 90% bound to serum albumin and alpha-1-acid glycoprotein.
80-85% bound primarily to albumin and alpha-1-acid glycoprotein
Volume of distribution is 0.35 L/kg, indicating limited extravascular distribution.
4-6 L/kg; large Vd indicates extensive tissue distribution
Oral bioavailability is approximately 85%; food may delay absorption but does not affect extent.
Sublingual: 70-90% (mean 80%); buccal: 50-65%; oral: ~30% due to first-pass metabolism
No dosage adjustment is recommended for patients with renal impairment.
No specific GFR-based dose adjustment recommended; use caution in severe renal impairment (Cr Cl <30 m L/min) due to potential accumulation of fentanyl.
No dosage adjustment is recommended for patients with hepatic impairment.
For Child-Pugh Class A or B: no adjustment required; for Child-Pugh Class C: reduce dose and monitor closely for toxicity due to reduced clearance.
Safety and efficacy have not been established in pediatric patients.
Not approved for pediatric patients <18 years; safety and efficacy not established.
No dosage adjustment is recommended based on age; clinical studies included patients ≥65 years, and no overall differences in safety or efficacy were observed.
Initiate at the lowest available dose (100 mcg) and titrate cautiously; elderly patients may have altered pharmacokinetics and increased sensitivity to fentanyl.
None
Risk of respiratory depression, addiction, abuse, and misuse; risk of accidental ingestion; risk of medication errors resulting in fatal overdose; life-threatening respiratory depression in opioid-non-tolerant patients; risk of opioid analgesic drug interactions with CNS depressants; risk of neonatal opioid withdrawal syndrome with prolonged use during pregnancy.
Contains preservative benzalkonium chloride, which may cause eye irritation and is adsorbable by soft contact lenses. Patients should remove contact lenses prior to administration and wait at least 15 minutes before reinserting.,Use with caution in patients with known hypersensitivity to any component of the product.,Not for injection. For topical ophthalmic use only.
Respiratory depression, QT prolongation, serotonin syndrome, adrenal insufficiency, severe hypotension, seizures, biliary tract disease, gastrointestinal obstruction, withdrawal syndrome, and risk of overdose with alcohol or other CNS depressants.
Hypersensitivity to lotilaner or any component of the formulation.
Hypersensitivity to fentanyl or any components; opioid-non-tolerant patients; acute or severe bronchial asthma; known or suspected gastrointestinal obstruction; concurrent use of MAOIs or within 14 days of discontinuation.
No clinically significant food interactions reported.
Avoid grapefruit and grapefruit juice during treatment as they inhibit CYP3A4, increasing fentanyl exposure. No other significant food interactions; however, avoid alcohol due to additive CNS depressant effects. Maintain consistent meal timing relative to dosing to minimize variability.
No adequate and well-controlled studies in pregnant women. In animal reproduction studies, no teratogenic effects were observed at exposures up to 5 times the human exposure at the recommended ophthalmic dose. Risk cannot be ruled out; use only if potential benefit justifies potential risk to fetus.
FDA Pregnancy Category C. First trimester: Inadequate human data; opioid analgesics are not associated with major malformations but may cause neural tube defects at high doses in animal studies. Second trimester: No specific malformation risk. Third trimester: Prolonged use can cause neonatal opioid withdrawal syndrome (NOWS) and respiratory depression at birth.
Unknown if excreted in human milk. No data on M/P ratio. Caution advised; consider developmental benefits of breastfeeding vs potential drug exposure.
Minimal excretion into breast milk; M/P ratio not reported. Fentanyl is poorly absorbed orally, making significant infant exposure unlikely. Monitor infant for sedation, respiratory depression, and poor feeding. Avoid use in breastfeeding mothers with opioid dependence or high doses.
No pharmacokinetic studies in pregnancy; no dose adjustment recommended.
Pregnancy increases clearance and volume of distribution, potentially reducing drug levels. Dose adjustments may be needed: initiate with lower doses and titrate to effect; consider increasing frequency or using breakthrough doses. Monitor for inadequate analgesia. Avoid abrupt discontinuation; taper if stopping.
XDEMVY (lotilaner ophthalmic solution) 0.25% is the first FDA-approved treatment for Demodex blepharitis. Administer one drop in each affected eye twice daily (approximately 12 hours apart) for 6 weeks. Shake well before use. Contact lenses should be removed prior to instillation and may be reinserted 15 minutes after dosing. Avoid touching the dropper tip to any surface to prevent contamination.
ABSTRAL (fentanyl sublingual spray) is a transmucosal immediate-release fentanyl (TIRF) formulation indicated for breakthrough pain in opioid-tolerant patients. Due to high bioavailability (~70%) and rapid onset (peak plasma concentration at 15-30 minutes), initial titration must start with 100 mcg, with dose escalation based on efficacy and tolerability. Weight-based conversion from other fentanyl products is not valid; utilize the provided conversion table. Patients must have a rescue agent (e.g., naloxone) available. Concomitant use with CYP3A4 inhibitors (e.g., ketoconazole, ritonavir) or inducers (e.g., rifampin, carbamazepine) requires dose adjustment. Avoid use in opioid-naïve patients due to risk of respiratory depression.
Use exactly as prescribed: one drop in each eye twice daily for 6 weeks.,Shake the bottle well before each use.,Remove contact lenses before applying and wait at least 15 minutes before reinserting.,Do not touch the dropper tip to your eye or any surface to avoid contamination.,If you miss a dose, apply as soon as you remember, but if it is close to the next dose, skip the missed dose and resume normal schedule.,Common side effects may include temporary stinging or blurred vision after application.
Use only for breakthrough cancer pain while on around-the-clock opioid therapy.,Do not switch from other fentanyl products based on dose; follow specific conversion instructions.,Spray entire dose into mouth; do not swallow or rinse for at least 10 minutes.,Store at room temperature, away from children and pets.,Dispose of unused units via drug take-back program or by flushing down toilet per FDA guidelines.,Never share this medication with others; death may occur.,Seek emergency if severe drowsiness, confusion, or slow breathing occurs.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about XDEMVY vs ABSTRAL, answered by our medical review team.
XDEMVY is a Antiparasitic Agent that works by XDEMVY (lotilaner ophthalmic solution) is a gamma-aminobutyric acid (GABA)-gated chloride channel antagonist. It inhibits the GABA-gated chloride channels in Demodex mites, leading to paralysis and death of the mites.. ABSTRAL is a Opioid Analgesic that works by Fentanyl is a potent mu-opioid receptor agonist, producing analgesia and sedation by activating G-protein coupled opioid receptors in the central nervous system.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between XDEMVY and ABSTRAL depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of XDEMVY is: 1 drop in each eye once daily in the evening for 6 weeks.. The standard adult dose of ABSTRAL is: For breakthrough pain in opioid-tolerant patients: initial dose 100 mcg sublingual tablet, titrate across strengths (100, 200, 300, 400, 600, 800 mcg) as needed; maximum 2 doses per episode, minimum 2 hours between episodes.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between XDEMVY and ABSTRAL in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. XDEMVY is classified as Category C. No adequate and well-controlled studies in pregnant women. In animal reproduction studies, no teratogenic effects were observed at exposures up to 5 times the human exposure at the. ABSTRAL is classified as Category C. FDA Pregnancy Category C. First trimester: Inadequate human data; opioid analgesics are not associated with major malformations but may cause neural tube defects at high doses in a. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.